U.S. Drinks Conference Hits New York

The U.S. Drinks Conference will tackle the challenge of how spirits, wine and beer brands can succeed in the competitive American beverage market. Held October 13 – 14 at the Helmsley Park Lane Hotel in Manhattan, the event is the first time the U.S. Drinks Conference will be held stateside – previous events occurred in London – and will present an expanded program.

“Based on feedback we received from last year’s conference we decided to extend the conference to two days to include a much wider range of subjects and speakers,” said Steve Raye, managing partner of Brand Action Team, which joins Next Level Marketing and MHW Ltd. in organizing the event. “Attendees expressed interest in a broader U.S. perspective and the opportunity to get answers to questions related to their individual business issues. We are changing the format to include more panel discussions and audience Q & A, to provide both the overview information, as well as respond to the specific and practical needs of the attending delegates.”

Trend data will be presented, along with real-life experiences, examples of brand success and information on the challenges facing marketing brands in the U.S. Featured speakers at the conference are on- and off-premise beverage leaders, including Michael Waterhouse of Dylan Prime and Chris Adams of Sherry-Lehmann. Top executives from companies including William Grant & Sons, Leblon Cachaca, Proximo Spirits, St-Germain and MHW Ltd., as well as beer executives from Heineken, Boston Beer Co. and Thomas Hooker Brewing will be on the program. Wine marketing executives from Winebow, Sopexa, Foster’s Group and Pernod Ricard also will be present, as will representatives of leading distributor companies and regulatory agencies.

For more information on the event, visit www.usdrinksconference.com.

Suggested Articles

A breakdown of the latest $1 trillion from the Senate.

The number of businesses switching from temporary to permanent closures surpasses 50%.

The coronavirus continues to threaten our industry but there are promising medical developments and still many questions on the next round of relief.